Radius Health (RDUS) Trading Up 5.1%

Radius Health Inc (NASDAQ:RDUS)’s share price was up 5.1% on Friday . The stock traded as high as $20.58 and last traded at $19.93. Approximately 1,306,240 shares traded hands during mid-day trading, an increase of 125% from the average daily volume of 580,906 shares. The stock had previously closed at $18.96.

Several equities analysts recently weighed in on RDUS shares. Zacks Investment Research raised shares of Radius Health from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Thursday, January 3rd. Cowen reissued a “hold” rating on shares of Radius Health in a research report on Tuesday, November 6th. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. HC Wainwright initiated coverage on shares of Radius Health in a research report on Thursday, February 14th. They set a “neutral” rating and a $22.00 target price on the stock. Finally, ValuEngine cut shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 2nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $41.88.

The stock has a market cap of $873.46 million, a P/E ratio of -4.08 and a beta of 0.96. The company has a current ratio of 5.50, a quick ratio of 5.39 and a debt-to-equity ratio of 1.85.

In related news, VP Joseph Francis Kelly purchased 3,000 shares of Radius Health stock in a transaction that occurred on Monday, December 17th. The shares were bought at an average price of $15.71 per share, for a total transaction of $47,130.00. Following the completion of the transaction, the vice president now directly owns 3,000 shares of the company’s stock, valued at $47,130. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Growth N. V. Biotech purchased 60,000 shares of Radius Health stock in a transaction that occurred on Thursday, December 20th. The shares were bought at an average price of $14.48 per share, for a total transaction of $868,800.00. Following the transaction, the insider now directly owns 6,710,276 shares of the company’s stock, valued at $97,164,796.48. The disclosure for this purchase can be found here. Insiders have bought a total of 123,000 shares of company stock valued at $1,854,330 over the last 90 days. Company insiders own 3.42% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in RDUS. HealthCor Management L.P. grew its holdings in shares of Radius Health by 77.0% during the third quarter. HealthCor Management L.P. now owns 3,584,580 shares of the biopharmaceutical company’s stock valued at $63,806,000 after buying an additional 1,559,580 shares during the last quarter. BB Biotech AG raised its holdings in shares of Radius Health by 6.3% in the 3rd quarter. BB Biotech AG now owns 6,590,276 shares of the biopharmaceutical company’s stock worth $117,307,000 after purchasing an additional 389,363 shares during the period. Man Group plc grew its stake in Radius Health by 352.6% in the 3rd quarter. Man Group plc now owns 496,037 shares of the biopharmaceutical company’s stock valued at $8,830,000 after buying an additional 386,437 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Radius Health by 503.7% during the 3rd quarter. Teachers Advisors LLC now owns 446,277 shares of the biopharmaceutical company’s stock valued at $7,944,000 after purchasing an additional 372,355 shares in the last quarter. Finally, Rubric Capital Management LP purchased a new position in shares of Radius Health during the 3rd quarter valued at $4,935,000.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2019/03/03/radius-health-rdus-trading-up-5-1.html.

Radius Health Company Profile (NASDAQ:RDUS)

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.

Featured Article: How does the Federal Reserve determine interest rates?

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit